Titre : Protéines d'inhibition de la différenciation

Protéines d'inhibition de la différenciation : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Acuity
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines d'inhibition de la différenciation : Questions médicales les plus fréquentes", "headline": "Protéines d'inhibition de la différenciation : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines d'inhibition de la différenciation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-25", "dateModified": "2025-04-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines d'inhibition de la différenciation" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs de transcription", "url": "https://questionsmedicales.fr/mesh/D014157", "about": { "@type": "MedicalCondition", "name": "Facteurs de transcription", "code": { "@type": "MedicalCode", "code": "D014157", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéine d'inhibition de la différenciation de type 1", "alternateName": "Inhibitor of Differentiation Protein 1", "url": "https://questionsmedicales.fr/mesh/D051798", "about": { "@type": "MedicalCondition", "name": "Protéine d'inhibition de la différenciation de type 1", "code": { "@type": "MedicalCode", "code": "D051798", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930.329.249" } } }, { "@type": "MedicalWebPage", "name": "Protéine d'inhibition de la différenciation-2", "alternateName": "Inhibitor of Differentiation Protein 2", "url": "https://questionsmedicales.fr/mesh/D051797", "about": { "@type": "MedicalCondition", "name": "Protéine d'inhibition de la différenciation-2", "code": { "@type": "MedicalCode", "code": "D051797", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930.329.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Protéines d'inhibition de la différenciation", "alternateName": "Inhibitor of Differentiation Proteins", "code": { "@type": "MedicalCode", "code": "D051796", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Francesco Balestri", "url": "https://questionsmedicales.fr/author/Francesco%20Balestri", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Roberta Moschini", "url": "https://questionsmedicales.fr/author/Roberta%20Moschini", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Umberto Mura", "url": "https://questionsmedicales.fr/author/Umberto%20Mura", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Mario Cappiello", "url": "https://questionsmedicales.fr/author/Mario%20Cappiello", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Antonella Del Corso", "url": "https://questionsmedicales.fr/author/Antonella%20Del%20Corso", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Mental health and visual acuity in patients with age-related macular degeneration.", "datePublished": "2022-10-02", "url": "https://questionsmedicales.fr/article/36183081", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12886-022-02602-9" } }, { "@type": "ScholarlyArticle", "name": "Factors associated with visual acuity improvement with a binocular digital therapeutic for amblyopia.", "datePublished": "2023-08-21", "url": "https://questionsmedicales.fr/article/37611818", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jaapos.2023.06.007" } }, { "@type": "ScholarlyArticle", "name": "Prevalence of Impairment of Visual Acuity and Severity of Retinopathy in Patients with Diabetes Mellitus.", "datePublished": "2022-08-08", "url": "https://questionsmedicales.fr/article/35940177", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/a-1752-0024" } }, { "@type": "ScholarlyArticle", "name": "Relationship between dynamic visual acuity and multiple object tracking performance.", "datePublished": "2022-06-06", "url": "https://questionsmedicales.fr/article/35668637", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/03010066221104281" } }, { "@type": "ScholarlyArticle", "name": "Diurnal Variation of Visual Acuity and Refraction in Fuchs Endothelial Corneal Dystrophy.", "datePublished": "2023-05-08", "url": "https://questionsmedicales.fr/article/37157119", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/ICO.0000000000003291" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Facteurs de transcription", "item": "https://questionsmedicales.fr/mesh/D014157" }, { "@type": "ListItem", "position": 5, "name": "Protéines d'inhibition de la différenciation", "item": "https://questionsmedicales.fr/mesh/D051796" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines d'inhibition de la différenciation - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines d'inhibition de la différenciation", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines d'inhibition de la différenciation", "description": "Comment diagnostiquer une anomalie des protéines d'inhibition ?\nQuels tests sont utilisés pour évaluer les niveaux de ces protéines ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels marqueurs tumoraux sont associés à ces protéines ?\nPeut-on utiliser l'imagerie pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Visual+Acuity&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines d'inhibition de la différenciation", "description": "Quels symptômes sont liés à une surproduction de ces protéines ?\nLes symptômes varient-ils selon le type de cancer ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Visual+Acuity&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines d'inhibition de la différenciation", "description": "Peut-on prévenir les anomalies des protéines d'inhibition ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLe tabagisme influence-t-il les niveaux de ces protéines ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Visual+Acuity&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines d'inhibition de la différenciation", "description": "Quels traitements ciblent les protéines d'inhibition ?\nLes traitements sont-ils efficaces contre tous les cancers ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils combinés avec d'autres thérapies ?\nComment évaluer l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Visual+Acuity&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines d'inhibition de la différenciation", "description": "Quelles complications peuvent survenir avec des niveaux anormaux ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nY a-t-il des complications spécifiques aux traitements ?\nLes complications peuvent-elles être prévenues ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Visual+Acuity&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines d'inhibition de la différenciation", "description": "Quels sont les principaux facteurs de risque associés ?\nL'âge influence-t-il le risque d'anomalies ?\nLe sexe joue-t-il un rôle dans le risque ?\nLe mode de vie affecte-t-il le risque ?\nY a-t-il des maladies associées à un risque accru ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Visual+Acuity&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des protéines d'inhibition ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de protéines peuvent être utilisés pour diagnostiquer." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les niveaux de ces protéines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et Western blot sont couramment utilisés pour mesurer les niveaux." } }, { "@type": "Question", "name": "Les biopsies peuvent-elles aider au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les biopsies peuvent révéler des niveaux anormaux de protéines d'inhibition." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont associés à ces protéines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme le CA-125 peuvent être associés à des niveaux anormaux." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à évaluer les tumeurs, mais pas directement les protéines." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une surproduction de ces protéines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une surproduction peut entraîner des symptômes liés à des tumeurs, comme la douleur." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de cancer ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon le type de cancer associé aux protéines." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez la fatigue, la perte de poids et des douleurs inexpliquées." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être similaires à ceux d'autres maladies, rendant le diagnostic difficile." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver à mesure que la maladie progresse ou se développe." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des protéines d'inhibition ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures de prévention, comme un mode de vie sain, peuvent aider." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des agents cancérigènes peut augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages réguliers peuvent aider à détecter des anomalies précocement." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut réduire le risque de cancer." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il les niveaux de ces protéines ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut altérer les niveaux de protéines et augmenter le risque de cancer." } }, { "@type": "Question", "name": "Quels traitements ciblent les protéines d'inhibition ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des inhibiteurs spécifiques peuvent être utilisés." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces contre tous les cancers ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'efficacité varie selon le type de cancer et le profil moléculaire." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les effets secondaires peuvent inclure des nausées, fatigue et immunosuppression." } }, { "@type": "Question", "name": "Les traitements sont-ils combinés avec d'autres thérapies ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent combinés avec la chimiothérapie ou la radiothérapie." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par imagerie et tests de suivi des niveaux de protéines." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des niveaux anormaux ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme la progression tumorale et la métastase peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Comment les complications affectent-elles le pronostic ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent aggraver le pronostic et réduire les chances de survie." } }, { "@type": "Question", "name": "Y a-t-il des complications spécifiques aux traitements ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements peuvent entraîner des complications comme l'infection." } }, { "@type": "Question", "name": "Les complications peuvent-elles être prévenues ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévenues par un suivi médical régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque associés ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de cancer et l'exposition à des toxines sont des facteurs clés." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'anomalies ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'anomalies augmente généralement avec l'âge." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains cancers liés aux protéines peuvent être plus fréquents chez un sexe." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Y a-t-il des maladies associées à un risque accru ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies auto-immunes peuvent augmenter le risque d'anomalies protéiques." } } ] } ] }

Sources (10000 au total)

Mental health and visual acuity in patients with age-related macular degeneration.

Visual acuity (VA) loss has been associated with depression in patients with age-related macular degeneration (AMD). However, previous studies did not incorporate subgroups of AMD when correlating VA ... AMD patients classified by multi-modal imaging were recruited into an AMD registry. Habitual VA was obtained by ophthalmic technicians using the Snellen VA at distance. At enrollment, patients complet... Eight hundred seventy-five patients were included in the study. Patients with bilateral geographic atrophy (GA) or bilateral GA and neovascular (NV) AMD scored lowest on the mental health subscales wi... There is a significant association between mental health questionnaire scores and AMD classification, as well as VA in both the better and worse-seeing eyes in patients with AMD. It is important for c...

Prevalence of Impairment of Visual Acuity and Severity of Retinopathy in Patients with Diabetes Mellitus.

No information exists on the frequency of visual impairment in people with diabetes mellitus (DM) in Germany. In this study, the prevalence of vision impairment in those individuals was investigated.... We retrospectively analyzed a cohort of 295 people (14221 consultations) at a university outpatient clinic with any type of DM and an available ETDRS-Score and visual acuity. The primary outcome was t... The prevalence of visual impairment in participants with DM was 11.2%; among these individuals, 81.8% had no or non-proliferative retinopathy. In the DM2 subgroup, 81.5% (n=22) of the visually impaire... The prevalence of impaired vision in people with diabetes in our cohort was 11.2%,<20% of visual impairment in people with diabetes is caused by diabetic retinopathy, and 69.7% of participants with vi...

Diurnal Variation of Visual Acuity and Refraction in Fuchs Endothelial Corneal Dystrophy.

Patients with advanced Fuchs endothelial corneal dystrophy frequently report poor vision in the morning, which improves as the day progresses. This study quantified the amount of variation in near and... This was a prospective cohort study. Best-corrected distance visual acuity and near visual acuity were tested in participants with clinically advanced Fuchs dystrophy and in controls with healthy corn... In Fuchs dystrophy, the mean distance visual acuity was worse by -3 letters (95% confidence interval, -4 to -1) directly after eye opening in the morning compared with late afternoon. No such differen... Distance and near visual acuity and refraction changes over the course of the day in patients with advanced Fuchs dystrophy. Although small changes in refraction may not usually require a second set o...

Pupil size effect on binocular summation for visual acuity and light disturbance.

Smaller pupil size under binocular conditions could justify partially the improvement of visual performance when compared to monocular conditions. The purpose of this study was to assess the binocular... Fifteen young subjects were recruited in this crossover study. Light disturbance index (LDI) was evaluated with the light disturbance analyzer and low (LCDVA) and high (HCDVA) contrast visual acuity w... Our results showed poorer visual performance in monocular than the binocular condition. An increasing deterioration was observed with the level of spherical defocus. Positive binocular summation for v... Binocular summation was observed under different conditions of spherical and cylindrical optical degradation of the image quality when the pupil size was fully controlled. This suggests that a neural ...

Impact of induced pseudomyopia and refractive fluctuations of accommodative spasm on visual acuity.

High-contrast visual acuity is disproportionately poor in patients with accommodative spasm subtype of near reflex (SNR-A), relative to uncorrected refractive errors of equivalent magnitude. This exag... To determine how combinations of pseudomyopic refraction and its temporal variations in SNR-A impact high-contrast visual acuity by inducing these patterns in healthy cyclopleged adults, relative to t... Refractive profiles of 15 patients with SNR-A were obtained from a previous study, averaged, and induced before the right eye of 14 cyclopleged adults (mean ±1 SD age: 22.7 ± 2.6 yrs) by feeding the p... The induced refractive fluctuations ranged from -0.80 to -1.75D, around a mean pseudomyopia of -1.20D. Visual acuity deterioration was maximum for the combination of pseudomyopia and temporal fluctuat... Combination of induced pseudomyopia and temporal fluctuations in refraction produces an additive loss of visual acuity and task precision, relative to baseline and each factor considered separately....

Cataract surgery in neovascular AMD: impact on visual acuity and disease activity.

Cataract and neovascular age-related macular degeneration (nAMD) often co-exist and both contribute to impaired vision. It has been debated whether cataract surgery can increase nAMD activity. The pur... Data was obtained from the Swedish Macular Register, the Swedish National Cataract Register, optical coherence tomography (OCT) images and patient charts. All eyes were treated at the Department of Op... In total, 156 patients (168 eyes) were included. The mean age at cataract surgery was 82 (standard deviation, SD 6) years. Both distance and near visual acuity improved after surgery. Distance visual ... Cataract surgery improved visual acuity in patients with on-going treatment for nAMD and did not affect anti-VEGF treatment intensity. Macular morphology remained unchanged. The slight increase in int...